Specifically, carriers of GIPR variants that are pharmacologically classified as loss-of-function variants with reduced cell surface expression, cAMP production, beta arrestin 2 recruitment, internalization, and endosomal signaling have consistently been associated with lower adiposity-related traits, including BMI (103) and nominally lower prevalence of obesity (39, 9799)
Health experts say the results are encouraging as they indicate that semaglutide may be an effective therapeutic option for treating comorbidities, and ultimately, improving peoples quality of life
10.4161/auto.19659 Autophagy 53 NiH
Gastrointestinal Issues Gastrointestinal issues, such as diarrhea and constipation, can occur with Semaglutide use
If your activity levels remain the same or increase, then your body will use stored fat for energy to make up the deficit